DUSA PHARMACEUTICALS INC Form 4/A

Form 4/A		
February	14,	2002

FORM 4	OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. SEE Instruction 1(b).	OMB Number: Estimated avera			
continue. SEE instruction 1(b).				
UNITED STATES SECURITE WASHINGTO	IES AND EXCHANGE ON, D.C. 20549	COMMISSION		
STATEMENT OF CHANGES	S IN BENEFICIAL (DWNERSHIP		
Filed pursuant to Section 16(a) of Section 17(a) of the Public Uti Section 30(f) of the Ir	ility Holding Cor	mpany Act of 1935 or		
(Print or Type Responses)				
1. Name and Address of Reporting Person	 on*			
Cooper Hill Partners, L.P.				
(Last) (First)	(Middle)			
230 Park Avenue				
(Street)				
New York, NY	10169			
(City) (State)	(Zip)			
2. Issuer Name and Ticker or Trading S	 Symbol			
DUSA Pharmaceuticals Inc. DUSA				
3. IRS or Social Security Number of Re	eporting Person	(Voluntary)		
4. Statement for Month/Year				
12/01 and through date hereof				
5. If Amendment, Date of Original (Mor 6/27/01	nth/Year)			
6. Relationship of Reporting Person(s)) to Issuer (Chec	ck all applicable)		
[] Director [X] 10% Owner				

				ve tit ify be	le below)					
7.	[] For	rm fi	led b	oy One	roup Filing Reporting te than One	Person		olicable Line Person	·	
 TAE	3LE I1	NON-D	ERIV	ATIVE	SECURITIES	ACQUIRE		DISPOSED OF,	OR BENEF	ICIALLY OW
1. Title of Security (Instr. 3)		 ty 2.	action Date	Trans- action Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				
				Day/ Year)	Code	. 0) V	- Amount	(A) or (D)	Price	
	nmon Sto		per	share	4/4/01	P		74,000	(P)	\$11.3125
	mon Sto		per	share	5/16/03	l P		9,600	(P)	\$13.52
	mon Sto		per	share	5/29/01	l P		18,900	(P)	\$12.10
	mon Storalue		per	share	6/4/01	P		4,600	(P)	\$11.70
	mon Storalue		per	share	8/2/01	P		2,200	(P)	\$13.70
	mon Sto		per	share	8/3/01	P		6,700	(P)	\$13.27
	nmon Sto		per	share	10/2/03	1 P		9,300	(S)	\$10.70
	mon Storvalue		 per	share	1/3/02	P		22,000	(S)	\$7.90
	nmon Sto	•	per	share	2/4/02	Р		2,400	(S)	\$4.45
	Amount Securit Benefic Owned a	ties ciall	У	Form	ership a: Direct or Indirect (Instr. 4)	ве Ве	dire nef			

of Month (Instr. 3 and 4)		(Instr.	4)	
374,700	(I)		ation of Respo	
Reminder: Report beneficially owne * If the form is Instruction 4(b (Over)	d directly or ind filed by more tha	directly.		es
(Over)				EC 1474 (7-96) Page 1 of 2
FORM 4 (continued TABLE II - DERIVA				
1. Title of Deriv	ative 2. Conver- r. 3) sion or	3. Transac- 4 tion Date e (Month/ f Day/ Year)	. Transac- 5	. Number of
				(A) (D)
6. Date Exer- cisable and Ex	7. Title and 7. of Underly			ber of ivative

piration Date (Month/Day/ Year)				Securi (Instr	ties . 3 and 4)	Security (Instr. 5)	Securities Beneficially Owned at	
Date	 e r-	Expira- tion Date		Title	Amount or Number of Shares		End of Month (Instr. 4)	
10.	Form Deri Secu Dire Indi	rship of vative rity: ct (D) or rect (I) tr. 4)		Nature Indire Benefi Owners (Instr	ct cial hip			
	1 2 2 2 +	ion of Dog	nong					

Explanation of Responses

Pursuant to an investment advisory contract, Cooper Hill Partners, L.P. currently has the power to vote and dispose of the securities held for the account of CLSP Overseas, Ltd. and, accordingly, may be deemed the "beneficial owner" of such securities. Mr. Casdin is the managing member of Casdin Capital, LLC, the general partner of Cooper Hill Partners, L.P.

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this form, one of which must be manually signed. If space is insufficient, SEE Instruction 6 for procedure.

/s/ Jeffrey Casdin 2/14/02
----By: Jeffrey Casdin Date

By: Jeffrey Casdin
For Casdin Capital, LLC,
General Partner of Cooper Hill
Partners, L.P., Investment Manager
of CSLP Overseas, Ltd.,
and Individually

**Signature of Reporting Person

Page 2 of 2